Hudock Inc’s Pacific Biosciences PACB Stock Holding History

Hudock Inc’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,063	Closed	-$23K	–	543
2022 Q3	$23K	Hold	4,063	–	–	0.01%	416
2022 Q2	$17K	Hold	4,063	–	–	0.01%	446
2022 Q1	$36K	Hold	4,063	–	–	0.01%	357
2021 Q4	$83K	Hold	4,063	–	–	0.02%	261
2021 Q3	$103K	Hold	4,063	–	–	0.03%	231
2021 Q2	$142K	Hold	4,063	–	–	0.04%	186
2021 Q1	$135K	Hold	4,063	–	–	0.04%	181
2020 Q4	$105K	Hold	4,063	–	–	0.03%	208
2020 Q3	$40K	Sell	4,063 -139	-3%	-$800	0.01%	300
2020 Q2	$14K	Sell	4,202 -240	-5%	-$817	0.01%	412
2020 Q1	$13K	Buy	4,442 +340	+8%	+$1.39K	0.01%	377
2019 Q4	$21K	Buy	4,102 +39	+1%	+$198	0.01%	343
2019 Q3	$20K	Hold	4,063	–	–	0.01%	349
2019 Q2	$24K	Hold	4,063	–	–	0.01%	323
2019 Q1	$29K	Hold	4,063	–	–	0.01%	298
2018 Q4	$29K	Buy	+4,063	New	+$25.7K	0.01%	289

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Hudock Inc's PACB Position: Q4 2022 in Review

Hudock Inc sold out of Pacific Biosciences (PACB) in Q4 2022, closing a stake of 4,063 shares — an estimated $23K sold.

Hudock Inc first reported a position in PACB in Q4 2018 and held it in 16 quarters. The position peaked at $142K in Q2 2021. 235 funds tracked by Wall St. Rank hold PACB as of Q4 2022.

Hudock Inc reported no remaining Pacific Biosciences position as of Q4 2022 after selling out during the quarter.
Hudock Inc sold 4,063 Pacific Biosciences shares in Q4 2022, an estimated $23K.
Hudock Inc first reported a position in Pacific Biosciences in Q4 2018 and held it in 16 quarters.
Hudock Inc's Pacific Biosciences position peaked at $142K in Q2 2021.
235 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2022.

Based on Hudock Inc's 13F filing for Q4 2022, filed 8 Feb 2023.